Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) (OTCPK:BAMXF) said it has received notification from the FDA regarding an extension of the review period for the marketing application of its experimental drug, ...

A breakthrough medical innovation that began life at Stevenage Bioscience Catalyst has become the first non-hormonal menopause treatment in its class to be approved by the UK’s Medicines and ...

Once-daily oral elinzanetant was associated with significantly reduced frequency of moderate to severe menopausal vasomotor symptoms compared with placebo, according to topline results from the ...

Elinzanetant significantly reduced vasomotor symptoms (VMS), also known as hot flashes, associated with menopause overall and across a range of body mass index (BMI) and smoking history subgroups ...

The U.S. Food and Drug Administration has extended its review of Bayer's experimental menopause relief drug, the German ...

Elinzanetant may address moderate to severe VMS by modulating a group of estrogen sensitive neurons in the hypothalamus region of the brain (the KNDy neurons) which, with the decrease of estrogen ...

Elinzanetant, the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, modulates the KNDy neurons, a group of estrogen sensitive neurons in the hypothalamus region of the brain.

Elinzanetant was associated with fewer and less severe menopausal vasomotor symptoms over 12 weeks. The neurokinin-1,3 receptor antagonist was associated with improved sleep and quality of life vs ...

Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate to severe VMS associated with menopause ...

Elinzanetant statistically significantly reduced the frequency of moderate to severe vasomotor symptoms from baseline to week 4 and 12 vs placebo. Topline results were announced from a phase 3 ...

The drug, deemed elinzanetant, can help reduced hot flashes and improve sleep for women experiencing menopause. Bayer has started trials on a new pill that could alleviate the struggles women face ...